In patients using it for weight management, the medication helps control appetite by promoting a sense of fullness and reducing cravings
Thats important because populations without type 2 diabetes may not be captured in pharmacy claims data alone, since off-label use of these medications is unlikely to be covered by insurers
The appeal of personalized medicine also influences this trend
at this dose, tirzeaptide drives ~8.3% weight loss compared to 6.6% for semaglutide over 40 weeks in the head-to-head SURPASS-2 trial in patients with obesity and T2D
And the psychological relationship with food has been fundamentally reset by months of recalibrated appetite signaling, a change that many participants describe as one of the most meaningful parts of the entire protocol
Another term is adiposity-based chronic disease, which focuses on adverse health outcomes that a person might be at risk for or develop from having excess weight